The Goldman Sachs Group Cuts LivaNova (NASDAQ:LIVN) Price Target to $55.00

LivaNova (NASDAQ:LIVN) had its price objective decreased by The Goldman Sachs Group from $64.00 to $55.00 in a report released on Monday,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock.

Other analysts have also issued research reports about the company. StockNews.com lowered LivaNova from a “strong-buy” rating to a “buy” rating in a report on Wednesday, February 26th. Wolfe Research lowered LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday, February 26th. Mizuho cut their price objective on LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a research report on Wednesday, February 26th. Stifel Nicolaus cut their price objective on LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Finally, Needham & Company LLC dropped their target price on LivaNova from $75.00 to $64.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, LivaNova currently has an average rating of “Buy” and a consensus target price of $62.20.

LivaNova Stock Performance

LIVN opened at $40.87 on Monday. The firm has a market capitalization of $2.22 billion, a P/E ratio of 97.31 and a beta of 1.10. The stock’s 50 day moving average price is $47.08 and its two-hundred day moving average price is $49.43. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. LivaNova has a 12-month low of $40.37 and a 12-month high of $64.47.

Insider Buying and Selling at LivaNova

In other news, Director Francesco Bianchi sold 1,250 shares of the company’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the transaction, the director now directly owns 7,522 shares of the company’s stock, valued at $383,546.78. This represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Russell Investments Group Ltd. raised its holdings in LivaNova by 17.1% during the fourth quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock worth $70,000 after acquiring an additional 219 shares in the last quarter. Sterling Capital Management LLC increased its stake in shares of LivaNova by 800.6% during the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company’s stock worth $75,000 after purchasing an additional 1,441 shares during the period. Central Pacific Bank Trust Division increased its stake in shares of LivaNova by 21.2% during the fourth quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock worth $191,000 after purchasing an additional 720 shares during the period. Captrust Financial Advisors bought a new position in shares of LivaNova during the third quarter worth approximately $217,000. Finally, Sanctuary Advisors LLC bought a new position in shares of LivaNova during the third quarter worth approximately $219,000. 97.64% of the stock is owned by institutional investors and hedge funds.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.